Home | Meeting coverage | ECCO 2022

Therapeutic Concepts: Discussions

ECCO 2022

F. Magro, S. Danese, A. Moschen, A. Dignaß, I. Dotan, F. Gomollón, S. Schreiber

The potential of histology in Crohn´s disease and how...

SERENITY

ECCO 2022

F. Magro, A. Moschen, A. Dignaß, I. Dotan, F. Gomollón, S. Schreiber

Combined endpoints as new therapy goals

SELECTION, GALAXI 1, LUCENT-1

ECCO 2022

F. Magro, A. Moschen, A. Dignaß, I. Dotan, F. Gomollón, S. Schreiber

Microbiota manipulation: Still a lot to learn

RESTORE-UC

ECCO 2022

F. Magro, S. Danese, A. Moschen, A. Dignaß, I. Dotan, F. Gomollón, S. Schreiber

Is the continuation of combination therapy the key to...

SPARE

ECCO 2022

F. Magro, S. Danese, A. Moschen, A. Dignaß, I. Dotan, F. Gomollón, S. Schreiber

Combination trials open a new door in IBD treatment

VEGA

ECCO 2022

F. Magro, S. Danese, A. Moschen, A. Dignaß, I. Dotan, F. Gomollón, S. Schreiber

Light at the end of the Pouchitis track

EARNEST, DIVERGENCE 2

Therapeutic Concepts – ENG

ECCO 2022

Silvio Danese, MD

Combination of biologics

VEGA

ECCO 2022

Gerhard Rogler, MD

Is stopping of therapy an option in CD?

SPARE

ECCO 2022

Massimo Claudio Fantini, MD

A new opportunity for proactive TDM disease control

NOR-DRUM B

ECCO 2022

Fernando Magro, MD

Withdrawal of infliximab or anti-metabolite therapy in...

SPARE

ECCO 2022

Gerhard Rogler, MD

FMT is not a promising option for UC patients

RESTORE-UC

ECCO 2022

Massimo Claudio Fantini, MD

The first combination therapy trial

VEGA

ECCO 2022

Fernando Magro, MD

Combination with different classes of drugs in moderate...

VEGA

ECCO 2022

Iris Dotan, MD

SPARE study in ECCO 2022

SPARE

ECCO 2022

Piotr Eder, MD

FMT in UC - still far away from the success story

RESTORE-UC

ECCO 2022

Peter Irving, MD

Proactive TDM

NOR-DRUM B

ECCO 2022

Alexander Moschen, MD

Combination of biologics - finally arrived in IBD!?

VEGA

ECCO 2022

Matthieu Allez, MD

Will we improve the management of IBD by combining...

VEGA

ECCO 2022

David Laharie, MD

A negative control trial for FMT in UC

RESTORE-UC

ECCO 2022

Peter Irving, MD

Ustekinumab for fistulizing disease

SEAVUE / STARDUST

ECCO 2022

David Laharie, MD

How to deescalate treatment in CD?

SPARE

ECCO 2022

Gerassimos Mantzaris, MD

Is the speedity of the steroid tapering important...

ECCO 2022

Alexander Moschen, MD

The interleukin-17 conundrum

ECCO 2022

Gerassimos Mantzaris, MD

Proactive TDM or SOC for monitoring infliximab...

NOR-DRUM B

ECCO 2022

James Lindsay, MD

Infliximab withdrawl leeds to a higher risk of...

SPARE

ECCO 2022

Peter Irving, MD

Filgotinib for fistulizing disease

DIVERGENCE 2

ECCO 2022

Axel Dignaß, MD

When to withdraw therapy in crohn's disease?

SPARE

Therapeutic Concepts – ITA/GER/AUT/GRE/FRA/POL/ISR/SUI

ECCO 2022

Iris Dotan, MD

מחקר SPARE ב ECCO 2022

SPARE

ECCO 2022

Piotr Eder, MD

FMT w colitis ulcerosa - wciąż daleko od sukcesu

RESTORE-UC

ECCO 2022

Matthieu Allez, MD

Allons nous améliorer la prise en charge des MICI en...

VEGA

ECCO 2022

Massimo Claudio Fantini, MD

Una nuova opportunità per i TDM nel controllo proattivo...

NOR-DRUM B

ECCO 2022

Gerhard Rogler, MD

Ist der Therapiestopp eine Option in CD?

SPARE

ECCO 2022

David Laharie, MD

Un essai négatif sur la transplantation de microbiote...

RESTORE-UC

ECCO 2022

Alexander Moschen, MD

Kombination von Biologika - endlich bei IBD...

VEGA

ECCO 2022

Gerassimos Mantzaris, MD

Προληπτική μέτρηση των θεραπευτικών επιπέδων του...

NOR-DRUM B

ECCO 2022

Alexander Moschen, MD

Das Interleukin-17 Rätsel

ECCO 2022

Axel Dignaß, MD

Wann Beendigung von Infliximab oder Immunmodulatoren...

SPARE

ECCO 2022

David Laharie, MD

Du nouveau sur l’allégement thérapeutique au cours de...

SPARE

ECCO 2022

Gerassimos Mantzaris, MD

Επηρεάζει η ταχύτητα διακοπής των κορτικοστεροειδών την...

ECCO 2022

Silvio Danese, MD

Combinazione di biologici

VEGA

ECCO 2022

Gerhard Rogler, MD

FMT ist kein vielversprechender Ansatz für UC-Patienten

RESTORE-UC

ECCO 2022

Massimo Claudio Fantini, MD

Il primo trial di terapia biologica di combinazione

VEGA

Targeting Safety: Discussions

ECCO 2022

A. Dignaß, S. Schreiber, D. Laharie, P. Eder, J. Lindsay, A. Armuzzi

Which IBD patients have a higher risk of safety...

Ecco 2022

A. Dignaß, S. Schreiber, D. Laharie, P. Eder, J. Lindsay, A. Armuzzi

COVID-19: still a moving target!

CLARITY IBD

ECCO 2022

A. Dignaß, S. Schreiber, D. Laharie, P. Eder, J. Lindsay, A. Armuzzi

Inflammatory bowel disease and cancer risk

ECCO 2022

A. Dignaß, S. Schreiber, D. Laharie, P. Eder, J. Lindsay, A. Armuzzi

Can we translate rheumatoid arthritis to ulcerative...

OCTAVE / RIVETING, DIVERGENCE 2, U-ACHIEVE

ECCO 2022

A. Dignaß, S. Schreiber, D. Laharie, P. Eder, J. Lindsay, A. Armuzzi

Is combination therapy safe?

VEGA

Targeting Safety – ENG

ECCO 2022

Alessandro Armuzzi, MD

The heart is apparently safe with continuous Ozanimod...

ECCO 2022

Alexander Moschen, MD

Breastmilk is tuning IBD risk

MECONIUM

ECCO 2022

Alessandro Armuzzi, MD

A touch of the near future in IBD treatment

VEGA

Targeting Safety – ITA/AUT

ECCO 2022

Alessandro Armuzzi, MD

Il cuore sembra essere apparentemente al sicuro durante...

ECCO 2022

Alexander Moschen, MD

Muttermilch beeinflusst das IBD-Risiko

MECONIUM

ECCO 2022

Alessandro Armuzzi, MD

Uno sguardo al prossimo futuro nel trattamento delle...

VEGA

Targeting Efficacy: Discussions

ECCO 2022

G. Mantzaris, M. Allez, M. C. Fantini, A. Dignaß, P. Irving, C. J. van der Woude, S. Schreiber

Fistulizing Crohn‘s disease - new treatment options...

SEAVUE / STARDUST, DIVERGENCE 2

ECCO 2022

G. Mantzaris, M. Allez, M. C. Fantini, A. Dignaß, P. Irving, C. J. van der Woude, S. Schreiber

The race is on IL-23 – exciting data for CD and UC

VEGA, GALAXI 1, QUASAR, LUCENT-1

ECCO 2022

G. Mantzaris, M. Allez, M. C. Fantini, A. Dignaß, P. Irving, C. J. van der Woude, S. Schreiber

Vedolizumab: promising data for pouchitis and IBD in...

EARNEST, VEDOKIDS, VEDOIBD

ECCO 2022

G. Mantzaris, M. Allez, M. C. Fantini, A. Dignaß, P. Irving, C. J. van der Woude, S. Schreiber

Mucosal healing: Will efficacy data translate into real...

ECCO 2022

G. Mantzaris, M. Allez, M. C. Fantini, A. Dignaß, P. Irving, C. J. van der Woude

Efficacy update on JAKis

U-ACHIEVE / U-ACCOMPLISH, SELECTION

Targeting Efficacy – ENG

ECCO 2022

Piotr Eder, MD

Upadacitinib - will it be the game changer in UC?

ECCO 2022

Stefan Schreiber, MD

Anti-IL-23 - a turning point?

QUASAR, GALAXI 1, LUCENT-1, FORTIFY

ECCO 2022

Axel Dignaß, MD

JAK inhibition

U-ACHIEVE / U-ACCOMPLISH, SELECTION / SELECTIONLTE, DIVERGENCE 2, OCTAVE / RIVETING

ECCO 2022

Piotr Eder, MD

Vedolizumab in chronic pouchitis - a new chapter in...

EARNEST

ECCO 2022

Fernando Gomollón, MD

New ways of treatment

ECCO 2022

James Lindsay, MD

Vedolizumab is effective in chronic pouchitis after...

EARNEST

ECCO 2022

Axel Dignaß, MD

Selective IL-23 blockade

QUASAR, GALAXI 1, LUCENT-1, FORTIFY

ECCO 2022

Silvio Danese, MD

Guselkumab as maintenace treatment in Crohn's Disease

GALAXI 1

ECCO 2022

Massimo Claudio Fantini, MD

New opportunity in pouchitis treatment

EARNEST

ECCO 2022

Fernando Magro, MD

Great news on pouchitis treatment - vedolizumab...

EARNEST

Targeting Efficacy – ITA/GER/ESP/POL

ECCO 2022

Stefan Schreiber, MD

Anti-IL-23 - eine Zeitenwende?

QUASAR, GALAXI 1, LUCENT-1, FORTIFY

ECCO 2022

Piotr Eder, MD

Wedolizumab w pouchitis - początek nowego rozdziału w...

EARNEST

ECCO 2022

Fernando Gomollón, MD

Nuevos caminos en el tratamiento

ECCO 2022

Axel Dignaß, MD

JAK-Inhibition

U-ACHIEVE / U-ACCOMPLISH, SELECTION / SELECTIONLTE, DIVERGENCE 2, OCTAVE / RIVETING

ECCO 2022

Silvio Danese, MD

Guselkumab come terapia di mantenimento

GALAXI 1

ECCO 2022

Axel Dignaß, MD

Selektive IL-23 Blockade

QUASAR, GALAXI 1, LUCENT-1, FORTIFY

ECCO 2022

Massimo Claudio Fantini, MD

Una nuova opportunità nel trattamemto della pouchite

EARNEST

ECCO 2022

Piotr Eder, MD

Upadacitinib - nowy lek, duże nadzieje

Treatment Goals – ENG

ECCO 2022

Axel Dignaß, MD

New therapy goals: urgency and disease clearance

LUCENT-1 and others

ECCO 2022

Fernando Magro, MD

Histological findings in mirikizumab treatment

SERENITY

ECCO 2022

Stefan Schreiber, MD

Disease control is possible!

SELECTION

ECCO 2022

Fernando Gomollón, MD

New goals for IBD

ECCO 2022

David Laharie, MD

Natural history of anal ulcerations in pediatric-onset...

EPIMAD registry

ECCO 2022

Fernando Magro, MD

New therapeutic goals in UC

SELECTION

ECCO 2022

James Lindsay, MD

Patient relevant outcomes also show efficacy of...

U-ACHIEVE

Treatment Goals – GER/FRA/ESP

ECCO 2022

David Laharie, MD

Histoire naturelle de la maladie de Crohn ano-périnéale...

EPIMAD registry

ECCO 2022

Axel Dignaß, MD

Urgency und Disease Clearance

LUCENT-1 and others

ECCO 2022

Stefan Schreiber, MD

Disease Control ist möglich!

SELECTION

ECCO 2022

Fernando Gomollón, MD

Nuevas objetivos en las EII

Targeting COVID-19 – ENG

ECCO 2022

Iris Dotan, MD

COVID-19 in patients with IBD stratified acc. to...

VIP, RECOVERI

ECCO 2022

Piotr Eder, MD

The efficacy of COVID-19 vaccines in IBD - what's new?

VIP, CLARITY IBD

Targeting COVID-19 – POL/ISR

ECCO 2022

Iris Dotan, MD

תגובה חיסונית לחיסונים כנגד קורונה בחולים עם מחלות מעי...

VIP, RECOVERI

ECCO 2022

Piotr Eder, MD

Skuteczność szczepień przeciw COVID-19 w IBD - nowe...

VIP, CLARITY IBD

Diagnostics and Prediction – ENG

ECCO 2022

Axel Dignaß, MD

Ultrasound as a predictor of treatment response

TRUST BEYOND

ECCO 2022

Axel Dignaß, MD

Point of Care Testing / AI / Telemedicine

Diagnostics and Prediction – GER

ECCO 2022

Axel Dignaß, MD

Ultraschall als Prädiktor des Therapieansprechens

TRUST BEYOND

ECCO 2022

Axel Dignaß, MD

Digitale Tools, KI und Telemedizin

Varia – ENG

ECCO 2022

Christien Janneke van der Woude, MD

ECCO guidelines on pregnancy

ECCO 2022

Fernando Gomollón, MD

Spanish women leading contribution to ECCO 2022

EITOS, VERSUS-CD, DUMBO

Varia – NLD/ESP

ECCO 2022

Christien Janneke van der Woude, MD

ECCO Richtlijnen zwangerschap

ECCO 2022

Fernando Gomollón, MD

Las mujeres lideran la contribución española a la ECCO...

EITOS, VERSUS-CD, DUMBO